Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
11
×
detroit top stories
life sciences
11
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
11
×
san francisco top stories
11
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
biotech
clinical trials
fda
cancer
eli lilly
pfizer
alzheimer's disease
bristol-myers squibb
celgene
ipo
merck
abbvie
astrazeneca
biogen
What
week
11
×
bio
roundup
drug
ipo
life
moves
science
biogen
companies
medical
alzheimer’s
big
biotechs
ceo
debut
firms
group
news
public
rolls
sciences
therapeutics
way
acquisitions
adu
aducanumab
america
american
amyloid
angst
annual
approved
arena’s
ash
assessed
attention
bagged
beats
bids
Language
unset
Current search:
week
×
" san francisco top stories "
×
" san francisco blog main "
×
" life sciences "
×
" detroit blog main "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
6 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M